Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Hold” from Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given an average rating of “Hold” by the eight analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $3.75.

A number of brokerages have weighed in on HOWL. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America lowered their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a report on Friday, December 19th.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL opened at $0.64 on Monday. Werewolf Therapeutics has a 12 month low of $0.56 and a 12 month high of $2.38. The company has a market cap of $31.30 million, a P/E ratio of -0.40 and a beta of 0.77. The business’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.27. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities analysts expect that Werewolf Therapeutics will post -1.56 EPS for the current year.

Insider Activity at Werewolf Therapeutics

In other news, major shareholder Ansbert Gadicke sold 140,488 shares of the stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the transaction, the insider owned 6,007,122 shares in the company, valued at approximately $7,328,688.84. This represents a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the transaction, the director directly owned 2,550,674 shares of the company’s stock, valued at $1,555,911.14. The trade was a 4.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 5,706,681 shares of company stock worth $6,342,622. 23.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its holdings in Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares in the last quarter. Nuveen LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. MPM Asset Management LLC boosted its stake in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares in the last quarter. MPM Bioimpact LLC grew its position in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the first quarter worth $79,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.